A Phase 1 interventional study of Donepezil Hydrochloride and Aricept® in Healthy, sponsored by Teva Pharmaceuticals USA. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-02-21.
Sponsored by Teva Pharmaceuticals USA (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study investigated the relative bioavailability (rate and extent of absorption) of Donepezil Hydrochloride Orally Disintegrating Tablets, 10 mg by Teva Pharmaceuticals, USA with that of Aricept® Orally Disintegrating Tablets, Manufactured and Marketed by Eisai Inc., following a single oral dose (1 x 10 mg orally disintegrating tablet) in healthy adult subjects administered under fasting conditions.
Teva Pharmaceuticals USA is the lead sponsor of 176 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
If female and:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Donepezil Hydrochloride 10 mg Orally Disintegrating Tablets
Drug: Donepezil Hydrochloride
Aricept® 10 mg Orally Disintegrating Tablets
Drug: Aricept®
10 mg Orally Disintegrating Tablet
10 mg Orally Disintegrating Tablet
Also known as: Donepezil Hydrochloride (generic name)
Cmax of Donepezil.
Bioequivalence based on Donepezil Cmax (maximum observed concentration of drug substance in plasma).
Time frame: Blood samples collected over a 72 hour period.
AUC0-t of Donepezil.
Bioequivalence based on Donepezil AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration).
Time frame: Blood samples collected over a 72 hour period.
| Milestone | Donepezil Hydrochloride (Test) First | Aricept® (Reference) First |
|---|---|---|
| Started | 13 | 13 |
| Completed | 13 | 12 |
| Not completed | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Milestone | Donepezil Hydrochloride (Test) First | Aricept® (Reference) First |
|---|---|---|
| Started | 13 | 12 |
| Completed | 9 | 10 |
| Not completed | 4 | 2 |
| Withdrew: Withdrawal by subject | 4 | 2 |
| Milestone | Donepezil Hydrochloride (Test) First | Aricept® (Reference) First |
|---|---|---|
| Started | 9 | 10 |
| Completed | 9 | 8 |
| Not completed | 0 | 2 |
| Withdrew: Emesis | 0 | 2 |
Bioequivalence based on Donepezil Cmax (maximum observed concentration of drug substance in plasma).
| ng/mL | Donepezil Hydrochloride (Test) | Aricept® (Reference) |
|---|---|---|
| Cmax of Donepezil. | 17800.27 ± 4515.36 | 17280.23 ± 4032.57 |
Bioequivalence based on Donepezil AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration).
| ng*h/mL | Donepezil Hydrochloride (Test) | Aricept® (Reference) |
|---|---|---|
| AUC0-t of Donepezil. | 466307.49 ± 85094.55 | 490716.21 ± 86199.11 |
Collected over Adverse event data was collected over the course of the study, which was approximately 8 weeks in duration.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Donepezil Hydrochloride (Test) First | — | 0/26 (0%) | 10/26 (38.5%) |
| Aricept® (Reference) First | — | 0/26 (0%) | 6/26 (23.1%) |
| Event | Donepezil Hydrochloride (Test) First | Aricept® (Reference) First |
|---|---|---|
| NauseaGeneral disorders | 5/26 | 4/26 |
| VomitingGeneral disorders | 5/26 | 3/26 |
| HeadacheGeneral disorders | 3/26 | 1/26 |
| DizzinessGeneral disorders | 0/26 | 2/26 |
| Abnormal DreamsGeneral disorders | 2/26 | 0/26 |
| Feeling HotGeneral disorders | 2/26 | 0/26 |
| Age, Categorical(Participants) | Donepezil Hydrochloride (Test) First | Aricept® (Reference) First | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 13 | 13 | 26 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Donepezil Hydrochloride (Test) First | Aricept® (Reference) First | Total |
|---|---|---|---|
| Female | 7 | 9 | 16 |
| Male | 6 | 4 | 10 |
| Race/Ethnicity, Customized(participants) | Donepezil Hydrochloride (Test) First | Aricept® (Reference) First | Total |
|---|---|---|---|
| Hispanic | 1 | 0 | 1 |
| Caucasian | 12 | 13 | 25 |
| Region of Enrollment(participants) | Donepezil Hydrochloride (Test) First | Aricept® (Reference) First | Total |
|---|---|---|---|
| United States | 13 | 13 | 26 |
The record gives a start of Apr 2006, a primary completion of May 2006 and a completion of May 2006. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2011, 4 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Donepezil